Use of antipsychotics in child and adolescent;Utilisation des antipsychotiques chez l'enfant et l'adolescent

Neuropsychiatrie de l'Enfance et de l'Adolescence

Volumn 60, Issue 1, 2012, Pages 12-19

  Bonnot, O ^a   Holzer, L ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antipsychotics; Efficacy; Metabolic syndrome; Side effects

Indexed keywords

NEUROLEPTIC AGENT;

ADOLESCENT; ARTICLE; AUTISM; BEHAVIOR DISORDER; BIPOLAR DISORDER; CHILD; CHILD PSYCHIATRY; CONSENSUS DEVELOPMENT; DRUG EFFICACY; DRUG TOLERABILITY; EUROPE; FRANCE; HUMAN; INTELLECTUAL IMPAIRMENT; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

EID: 84856790326     PISSN: 02229617     EISSN: 17696615     Source Type: Journal    
DOI: 10.1016/j.neurenf.2011.07.003     Document Type: Article

References (66)

1. Merikangas K.R., He J.P., Burstein M., Swanson S.A., Avenevoli S., Cui L., et al. Lifetime prevalence of mental disorders in U. S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry. 2010, 49(10):980-989.
2. Hugtenburg J.G., Heerdink E.R., Tso Y.H. Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatr. 2005, 94(10):1484-1487.
3. Acquaviva E., Legleye S., Auleley G.R., Deligne J., Carel D., Falissard B.B. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry. 2009, 9:72.
4. Woods S.W., Martin A., Spector S.G., McGlashan T.H. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry. 2002, 41(12):1439-1446.
5. Bonnot O., Inaoui R., Lloret C., Cohen D. Surveillance of metabolic syndrome, hyperprolactinemia and cardiac side effects in children and adolescent treated with antipsychotic. Actuality and recommendations. Neuropsychiatr Enfance Adolesc 2009, 58(6-7):339-340. 10.1016/j.neurenf.2009.09.004.
6. Correll C.U., Manu P., Olshanskiy V., Napolitano B., Kane J.M., Malhotra A.K. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009, 302(16):1765-1773.
7. Bonnot O., Cohen D. Les schizophrènies à début précoce. Psychiatrie de l'Enfant. 2011, 270-279. Lavoisier, Paris. A. Danion-Grillat, C. Bursztejn (Eds.).
8. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., et al. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005, 80(1):9-18.
9. Citrome L., Stroup T.S. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. Int J Clin Pract. 2006, 60(8):933-940.
10. Armenteros J.L., Davies M. Antipsychotics in early onset Schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2006, 15(3):141-148.
11. Haas M., Eerdekens M., Kushner S., Singer J., Augustyns I., Quiroz J., et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009, 194(2):158-164.
12. Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008, 165(11):1432-1441.
13. Kryzhanovskaya L., Schulz S.C., McDougle C., Frazier J., Dittmann R., Robertson-Plouch C., et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009, 48(1):60-70.
14. Sikich L., Frazier J.A., McClellan J., Findling R.L., Vitiello B., Ritz L., et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008, 165(11):1420-1431.
15. Kumra S., Kranzler H., Gerbino-Rosen G., Kester H.M., De Thomas C., Kafantaris V., et al. Clozapine and " high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008, 63(5):524-529.
16. Jensen J.B., Kumra S., Leitten W., Oberstar J., Anjum A., White T., et al. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 2008, 18(4):317-326.
17. Haas M., Unis A.S., Armenteros J., Copenhaver M.D., Quiroz J.A., Kushner S.F. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009, 19(6):611-621.
18. Shaw P., Sporn A., Gogtay N., Overman G.P., Greenstein D., Gochman P., et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006, 63(7):721-730.
19. Kim-Cohen J., Caspi A., Moffitt T.E., Harrington H., Milne B.J., Poulton R. Prior juvenile diagnoses in adults with mental disorder: developmental follow-back of a prospective-longitudinal cohort. Arch Gen Psychiatry. 2003, 60(7):709-717.
20. Carlson G.A. Treating the childhood bipolar controversy: a tale of two children. Am J Psychiatry. 2009, 166(1):18-24.
21. Gramond A., Consoli A., Maury M., Purper D. Les Thymorégulateurs chez l'enfant et l'adolescent. Neuropsychiatr Enfance Adolesc 2011, [in press]. 10.1016/j.neurenf.2011.08.001.
22. Consoli A., Deniau E., Huynh C., Purper D., Cohen D. Treatments in child and adolescent bipolar disorders. Eur Child Adolesc Psychiatry. 2007, 16(3):187-198.
23. Findling R.L., Nyilas M., Forbes R.A., McQuade R.D., Jin N., Iwamoto T., et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009, 70(10):1441-1451.
24. Haas M., Delbello M.P., Pandina G., Kushner S., Van Hove I., Augustyns I., et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009, 11(7):687-700.
25. Pavuluri M.N., Henry D.B., Findling R.L., Parnes S., Carbray J.A., Mohammed T., et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 2010, 12(6):593-605.
26. Tohen M., Kryzhanovskaya L., Carlson G., Delbello M., Wozniak J., Kowatch R., et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007, 164(10):1547-1556.
27. Tramontina S., Zeni C.P., Ketzer C.R., Pheula G.F., Narvaez J., Rohde L.A. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009, 70(5):756-764.
28. Wozniak J., Mick E., Waxmonsky J., Kotarski M., Hantsoo L., Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009, 19(5):539-545.
29. Youngstrom E.A., Danielson C.K., Findling R.L., Gracious B.L., Calabrese J.R. Factor structure of the Young Mania Rating Scale for use with youths ages 5to 17years. J Clin Child Adolesc Psychol 2002, 31(4):567-572.
30. Marcelli D., Cohen D. Enfance et psychopathologie 2008, Masson, Paris.
31. Winterfeld U., Le Heuzey M.F., Acquaviva E., Mouren M.C., Brion F., Bourdon O. Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital. Pharm World Sci. 2008, 30(5):600-604.
32. Nagaraj R., Singhi P., Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol. 2006, 21(6):450-455.
33. Luby J., Mrakotsky C., Stalets M.M., Belden A., Heffelfinger A., Williams M., et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006, 16(5):575-587.
34. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004, 114(5):e634-e641.
35. McCracken J.T., McGough J., Shah B., Cronin P., Hong D., Aman M.G., et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002, 347(5):314-321.
36. Hollander E., Wasserman S., Swanson E.N., Chaplin W., Schapiro M.L., Zagursky K., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006, 16(5):541-548.
37. McDougle C.J., Stigler K.A., Erickson C.A., Posey D.J. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008, 69(Suppl. 4):15-20.
38. American Psychiatric Association Diagnostic and statistical manual of mental disorders DSM-IV-TR (Text Revision) 2000, American Psychiatric Association, Whashington, DC. 4th edition.
39. Aman M.G., De Smedt G., Derivan A., Lyons B., Findling R.L. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry. 2002, 159(8):1337-1346.
40. Findling R.L., Aman M.G., Eerdekens M., Derivan A., Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry. 2004, 161(4):677-684.
41. Croonenberghs J., Fegert J.M., Findling R.L., De Smedt G., Van Dongen S. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504patients. J Am Acad Child Adolesc Psychiatry. 2005, 44(1):64-72.
42. Findling R.L. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry. 2008, 69(Suppl. 4):9-14.
43. Saland J.M. Update on the metabolic syndrome in children. Curr Opin Pediatr. 2007, 19(2):183-191.
44. Malone R.P., Cater J., Sheikh R.M., Choudhury M.S., Delaney M.A. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001, 40(8):887-894.
45. Frazier J.A., Biederman J., Tohen M., Feldman P.D., Jacobs T.G., Toma V., et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001, 11(3):239-250.
46. Ratzoni G., Gothelf D., Brand-Gothelf A., Reidman J., Kikinzon L., Gal G., et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002, 41(3):337-343.
47. Grothe D.R., Calis K.A., Jacobsen L., Kumra S., DeVane C.L., Rapoport J.L., et al. Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol. 2000, 20(2):220-225.
48. Keltner N.L. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics. Perspect Psychiatr Care. 2006, 42(3):204-207.
49. Armenteros J.L., Whitaker A.H., Welikson M., Stedge D.J., Gorman J. Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 1997, 36(5):694-700.
50. Findling R.L., Maxwell K., Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull. 1997, 33(1):155-159.
51. Kelly D.L., Conley R.R., Love R.C., Horn D.S., Ushchak C.M. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998, 8(3):151-159.
52. Martin A., Landau J., Leebens P., Ulizio K., Cicchetti D., Scahill L., et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child. Adolesc Psychopharmacol 2000, 10(4):259-268.
53. Gothelf D., Falk B., Singer P., Kairi M., Phillip M., Zigel L., et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry. 2002, 159(6):1055-1057.
54. Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 2008, 69(Suppl. 4):21-25.
55. Ehret M., Goethe J., Lanosa M., Coleman C.I. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010, 71(10):1286-1292.
56. Langer G., Sachar E.J., Gruen P.H., Halpern F.S. Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature. 1977, 266(5603):639-640.
57. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997, 17(5):407-418.
58. Breier A.F., Malhotra A.K., Su T.P., Pinals D.A., Elman I., Adler C.M., et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry. 1999, 156(2):294-298.
59. David S.R., Taylor C.C., Kinon B.J., Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000, 22(9):1085-1096.
60. Szarfman A., Tonning J.M., Levine J.G., Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006, 26(6):748-758.
61. Sporn A.L., Vermani A., Greenstein D.K., Bobb A.J., Spencer E.P., Clasen L.S., et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry. 2007, 46(10):1349-1356.
62. Holzer L., Eap C.B. Risperidone-induced symptomatic hyperprolactinaemia in adolescents. J Clin Psychopharmacol. 2006, 26(2):167-171.
63. van Kooten M., Arends J., Cohen D. Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection. J Clin Psychopharmacol. 2011, 31(1):126-128.
64. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry. 2007, 190:129-134.
65. Bonnot O., Inaoui R., Raffin-Viard M., Bodeau N., Coussieux F., Cohen D. Children and adolescents with severe mental illness need Vitamin D supplementation regardless of disease or treatment. J Child Adolesc Psychopharmacol 2011, 21(2):157-161.
66. Jaquenoud Sirot E., van der Velden J.W., Rentsch K., Eap C.B., Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf. 2006, 29(9):735-768.